ALT NASDAQ
Credit Risk of going bust: higher than 56% of companies Debt: 8.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 99%), Altimmune, Inc. would be worth roughly what it owes.
Total debt $35.7M against a stock market value of $396.8M.
Distance to default 4.61 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.4M (short-term plus half of long-term), stock volatility 67.8%; Altman Z'' 7.93. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Gaithersburg, MD 20878
US
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Arbet-Engels Christo | M-Exempt | 37,500 | — | 2026-10-01 |
| Arbet-Engels Christo | F-InKind | 12,679 | $2.76 | 2026-10-01 |
| Arbet-Engels Christo | M-Exempt | 37,500 | — | 2026-10-01 |
| WEAVER GREGORY L | M-Exempt | 14,475 | — | 2026-10-01 |
| WEAVER GREGORY L | F-InKind | 4,379 | $2.76 | 2026-10-01 |